Related Experiment Video
Updated: Jun 16, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
The emerging field of viroimmunotherapy for pediatric brain tumors
Marc Garcia-Moure1, Virginia Laspidea2, Sumit Gupta3
1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Pediatric brain tumors are the most common solid tumors in children. Even to date, with the advances in multimodality therapeutic management, survival outcomes remain dismal in some types of tumors, such as pediatric-type diffuse high-grade gliomas or central nervous system embryonal tumors. Failure to understand the complex molecular heterogeneity and the elusive tumor and microenvironment interplay continues to undermine therapeutic efficacy. Developing a strategy that would improve survival for these fatal tumors remains unmet in pediatric neuro-oncology. Oncolytic viruses (OVs) are emerging as a feasible, safe, and promising therapy for brain tumors. The new paradigm in virotherapy implies that the direct cytopathic effect is followed, under certain circumstances, by an antitumor immune response responsible for the partial or complete debulking of the tumor mass. OVs alone or combined with other therapeutic modalities have been primarily used in adult neuro-oncology. A surge in encouraging preclinical studies in pediatric brain tumor models recently led to the clinical translation of OVs with encouraging results in these tumors. In this review, we summarize the different virotherapy tested in preclinical and clinical studies in pediatric brain tumors, and we discuss the limitations and future avenues necessary to improve the response of these tumors to this type of therapy.
Insights
Oncolytic viruses (OVs) show promise for treating pediatric brain tumors, offering a new therapeutic strategy. This review explores OV applications in children, highlighting their potential to improve survival rates for these aggressive cancers.
Area of Science:
- Neuro-oncology
- Virology
- Pediatric oncology
Background:
- Pediatric brain tumors are the leading cause of cancer-related death in children.
- Current treatments for aggressive pediatric brain tumors like diffuse high-grade gliomas have limited efficacy.
- Understanding tumor heterogeneity and microenvironment interactions is crucial for treatment development.
Purpose of the Study:
- To review oncolytic virus (OV) therapies for pediatric brain tumors.
- To discuss the current preclinical and clinical applications of virotherapy in this patient population.
- To identify limitations and future directions for improving OV treatment efficacy.
Main Methods:
- Review of preclinical studies involving oncolytic viruses in pediatric brain tumor models.
- Analysis of clinical trial data for oncolytic virus therapies in pediatric neuro-oncology.
- Synthesis of current knowledge on virotherapy mechanisms, including direct oncolysis and immune response.
Main Results:
- Oncolytic viruses demonstrate feasibility, safety, and promise in pediatric brain tumor models.
- Clinical translation of OV therapy in pediatric neuro-oncology has yielded encouraging initial results.
- Virotherapy can induce direct tumor cell killing and stimulate antitumor immune responses.
Conclusions:
- Oncolytic viruses represent a promising therapeutic avenue for pediatric brain tumors.
- Further research is needed to overcome limitations and optimize OV treatment strategies.
- Combination therapies and a deeper understanding of tumor-microenvironment interplay are key for future success.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...